Compare FWRD & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | OCGN |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.9M | 474.8M |
| IPO Year | 2024 | 2014 |
| Metric | FWRD | OCGN |
|---|---|---|
| Price | $16.40 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $37.50 | $9.75 |
| AVG Volume (30 Days) | 530.4K | ★ 3.7M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,573,000.00 | N/A |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $6.66 | $1,718.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.86 | $1.01 |
| 52 Week High | $31.30 | $2.73 |
| Indicator | FWRD | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 46.69 |
| Support Level | $14.82 | $1.30 |
| Resistance Level | $16.77 | $1.49 |
| Average True Range (ATR) | 0.78 | 0.07 |
| MACD | -0.38 | -0.00 |
| Stochastic Oscillator | 4.06 | 19.05 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").